US006726932B2

(12) **United States Patent**
Konishi

(10) **Patent No.: US 6,726,932 B2**
(45) **Date of Patent: Apr. 27, 2004**

(54) **FATTY ACID-CONTAINING COMPOSITION**

(75) Inventor: **Jin-emon Konishi**, Osaka (JP)

(73) Assignee: **Nippon Zoki Pharmaceutical Co., Ltd.**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/788,007**

(22) Filed: **Feb. 16, 2001**

(65) **Prior Publication Data**

US 2003/0018011 A1 Jan. 23, 2003

(30) **Foreign Application Priority Data**

Feb. 18, 2000 (JP) 2000-041327

(51) **Int. Cl.**[7] **A61K 9/14**

(52) **U.S. Cl.** **424/489**; 424/451; 424/464; 424/422; 424/484; 424/486; 424/499; 424/501; 424/502; 424/78.08

(58) **Field of Search** 424/78.08, 422, 424/484, 486, 489, 499, 501, 502, 451, 464

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,959,566 A		5/1976	Pangonis	
4,036,787 A		7/1977	Blount	
4,039,474 A		8/1977	Feistel et al.	
4,056,937 A		11/1977	Suzuki	
4,089,883 A		5/1978	Blount	
4,138,421 A		2/1979	Blount	
4,145,415 A		3/1979	Sato	
4,640,361 A		2/1987	Smith et al.	
4,863,518 A		9/1989	Blount	
4,879,297 A		11/1989	Mahjour et al.	
4,985,254 A		1/1991	Konishi	
4,985,354 A		1/1991	Toyomaki et al.	
5,013,558 A		5/1991	Konishi	
5,057,324 A		10/1991	Shibayama et al.	
5,127,994 A		7/1992	Johansson	
5,227,089 A		7/1993	Hasegawa et al.	
5,523,295 A		6/1996	Fasman	
5,534,509 A		7/1996	Konishi et al.	
5,560,935 A		10/1996	Konishi et al.	
5,576,025 A	*	11/1996	Akiyama et al.	424/501
5,658,896 A		8/1997	Konishi et al.	
5,767,103 A		6/1998	Greenberg et al.	
5,807,951 A	*	9/1998	Konishi et al.	527/300
6,051,613 A		4/2000	Ohno et al.	
6,165,515 A		12/2000	Matsuyama et al.	
6,365,192 B1		4/2002	Konishi	

FOREIGN PATENT DOCUMENTS

EP	0 300 973	1/1989
EP	0 315 591 A2	5/1989
EP	0 341 209 A2	11/1989
EP	0 348 353 A2	12/1989
EP	0 621 038 A1	10/1994
EP	0 645 142 A1	3/1995
EP	0 733 636 A1	9/1996
EP	0 919 238 A3	6/1999
EP	0 953 352 A1	11/1999
FR	2 610 523	8/1988
FR	2 671 488	7/1992
FR	2 720 068	11/1995
GB	697351	9/1953
JP	53-101515	9/1978
JP	57-77697	5/1982
JP	57-183720	11/1982
JP	58-35117	3/1983
JP	58-121217	7/1983
JP	62-145022	6/1987
JP	2-73020	3/1990
JP	3-43279	7/1991
JP	3-204803	9/1991
JP	2594222	12/1996
JP	63-25600	5/1998
JP	63-039572	8/1998
WO	WO 93/08828	5/1993
WO	WO 97/05903 A	2/1997
WO	WO 98/13377	4/1998

OTHER PUBLICATIONS

Yokoi, et al., "Effect of Degree of Polymerization of Silicic Acid on the Gastrointestinal Absorption of Silicate in Rats", *Chem. Pharm. Bull.*, vol. 27, No. 8, 1979, pp. 1733–9.

The Merck Index, Ninth Edition, Nos. 7456,8443,8232–8243, and 5514–5515 (1976).

Database Biosis, XP–002113089, Li S–Y et al., Studies on the Protective Action of Silicon Compound of Equisetum Against Experimental Liver Injury in Rats and Mice & Zhongguo Yaolixue Yu Dulixue Zazhi. ISSN: 1000–3002, abstract.

(List continued on next page.)

Primary Examiner—Thurman K. Page
Assistant Examiner—Liliana Di Nola-Baron
(74) *Attorney, Agent, or Firm*—Hollander Law Firm, P.L.C.

(57) **ABSTRACT**

The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water soluble silicate polymers used according to the present invention may be obtained by polymerization and/or by extraction from plants, animals or fungi, or inflammatory tissue. The saturated fatty acid contained as an effective ingredient in the pharmaceutical composition of the present invention may be a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms. The saturated fatty acid and water-soluble silicate polymer, effective ingredients of the present invention, can be formulated for various pharmaceutical compositions by combining with a suitable carrier or diluent for medical use. The composition of the present invention can suppress histamine release induced by a structural change in the cell membrane of the mast cell. It exhibits an excellent organism maintaining function such as cell protecting action and, therefore, is useful as a medicine such as an anti-allergic or anti-inflammatory agent.

27 Claims, No Drawings